New IL-1 Beta Inhibitor Shows Promising Results for Severe Skin Condition
Phase II trial results presented at the European Academy of Dermatology and Venereology meeting showed that abdakibart, an investigational interleukin-1 beta inhibitor, significantly improved symptoms in patients with hidradenitis suppurativa. Over 40% of treated patients achieved a high response rate compared to just 25% on placebo, with benefits seen as early as week four. The drug showed a favorable safety profile with minimal serious adverse events.
At the 2026 European Academy of Dermatology and Venereology (EADV) meeting in Vienna, new data from the Phase II LOTUS trial demonstrated that abdakibart, an investigational interleukin-1 beta inhibitor developed by Avalo Therapeutics, significantly improved symptoms in patients with hidradenitis suppurativa (HS). The study included over 240 participants, with approximately 80 assigned to each of two abdakibart dose groups and a placebo group. By week 16, 43% of patients receiving either dose achieved HiSCR75—a measure of high response rate—compared to only 25% in the placebo group. This marked one of the highest efficacy rates observed in any Phase II HS trial to date. Notably, clinical improvements were evident as early as week four, indicating rapid onset of action. The drug showed a favorable safety profile over the 16-week period, with no increased risk of infection despite HS patients’ typical comorbidities; common side effects included mild headaches and injection site reactions, which occurred at similar rates across all groups.
The findings build on growing interest in targeting inflammatory pathways like IL-1 beta in chronic skin diseases. Prior treatments for HS—such as biologics targeting TNF-alpha or IL-17—have shown limited efficacy in some patients, underscoring the need for novel mechanisms. Dr. Martina J. Porter of Beth Israel Deaconess Medical Center, who presented the results, emphasized that abdakibart’s early separation from placebo and clean safety da
The emergence of abdakibart could significantly impact the lives of the estimated 1–4% of people affected by hidradenitis suppurativa, a chronic, painful skin condition often linked to depression, social isolation, and reduced quality of life. If confirmed in larger trials, this IL-1 beta inhibitor may offer a new treatment option for patients who do not respond to current biologics, potentially reducing the burden on healthcare systems through fewer flare-ups and hospitalizations. The pharmaceutical market for HS therapies is expanding, with companies like Pfizer and AbbVie already investing heavily; abdakibart’s success could shift competitive dynamics. A comparable precedent is the introduction of adalimumab (Humira), which transformed treatment for psoriasis and later became a benchmark in inflammatory skin diseases. However, unlike Humira, which faced long-term safety concerns, abdakibart’s early safety data are encouraging. What may follow is increased investor interest in IL-1 p